ArticleBioinformation2025
Current trends on immunotherapy for oncology.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on the molecular mechanisms of PD-1 and LAG-3 synergy in regulating T cell exhaustion and immunotherapy.Annals of medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has revolutionized oncology by harnessing the patient's own immune system to recognize and eliminate tumor cells, leading to durable responses in a variety of malignancies. Over the past decade, immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1 have become standard of care across multiple solid tumors, while chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in hematologic cancers. Despite these successes, challenges such as primary and acquired resistance, immune-related toxicities, and high treatment costs continue to limit broader application. Emerging strategies including novel checkpoint targets (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.